The U.S. Food and Drug Administration (FDA) has given clearance to the Elecsys pTau181 blood test, developed by Roche Diagnostics in partnership with Eli Lilly. This test is intended to aid in the initial assessment for Alzheimer's disease in patients aged 55 and older who are presenting with signs, symptoms, or complaints of cognitive decline. This marks a significant development as it is the first blood test of its kind to be cleared for use in a primary care setting.
The Elecsys pTau181 test measures pTau181, a key protein associated with Alzheimer's disease. Its primary utility lies in helping clinicians rule out Alzheimer's-related pathology, with a reported 97.9% negative predictive value. This allows healthcare providers to identify patients who are unlikely to have Alzheimer's, thereby enabling them to explore other potential causes for cognitive decline more efficiently. For those with a positive result, further confirmatory testing is recommended.
This approval follows the FDA's nod for Fujirebio Diagnostics' Lumipulse blood test in May, which was the first device approved for diagnosing the brain-wasting condition. The introduction of blood tests like Elecsys pTau181 is expected to revolutionize Alzheimer's diagnosis by offering a rapid, non-invasive alternative to traditional, often costly, or uncomfortable methods such as spinal taps. This accessibility is crucial for speeding up diagnosis and facilitating earlier access to treatments like Biogen and Eisai's Leqembi and Eli Lilly's Kisunla, which have seen modest sales due to diagnostic challenges.
Roche and Eli Lilly initiated their collaboration to develop this blood test, with a clinical trial involving hundreds of volunteers aiming for a 2025 regulatory filing. Cagri Senyucel, chief medical officer and senior vice president, medical and scientific affairs at Roche, highlighted that bringing reliable, minimally invasive blood testing into primary care will help physicians and patients get answers sooner in their diagnostic journey. However, the test results should be used in conjunction with other clinical information to confirm an Alzheimer's diagnosis, as relying on the test in isolation could lead to diagnostic errors.
Brad Moore, president and CEO of Roche Diagnostics North America, emphasized that this development will help identify patients unlikely to have Alzheimer’s disease earlier, thereby focusing specialty resources where they are most needed. The broader availability of such tests is particularly important given that more than 2 in 5 people over the age of 55 are estimated to be at risk for cognitive decline.
